We are live on ! Find out more
PCRX icon

Pacira BioSciences

187 hedge funds and large institutions have $3.03B invested in Pacira BioSciences in 2015 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 73 increasing their positions, 63 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more call options, than puts

Call options by funds: $31.6M | Put options by funds: $24.3M

16% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 63

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

9% less funds holding

Funds holding: 205187 (-18)

15% less capital invested

Capital invested by funds: $3.58B → $3.03B (-$553M)

34% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 47

Holders
187
Holders Change
-18
Holders Change %
-8.78%
% of All Funds
5.04%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
31
Increased
73
Reduced
63
Closed
47
Calls
$31.6M
Puts
$24.3M
Net Calls
+$7.32M
Net Calls Change
+$7.3M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$273M -$35.5M -450,394 -10%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$249M +$15.9M +202,073 +6%
JHIU
3
Janus Henderson Investors US
Colorado
$232M +$124M +1,569,892 +91%
GGHC
4
Gilder Gagnon Howe & Co
New York
$196M -$8.58M -108,903 -4%
Vanguard Group
5
Vanguard Group
Pennsylvania
$164M +$6.46M +82,059 +4%
MCM
6
Marsico Capital Management
Colorado
$161M +$26.1M +331,788 +17%
Jennison Associates
7
Jennison Associates
New York
$118M -$92.5M -1,174,059 -41%
BFA
8
BlackRock Fund Advisors
California
$115M +$1.6M +20,337 +1%
Westfield Capital Management
9
Westfield Capital Management
Massachusetts
$106M +$60.3M +766,062 +105%
Invesco
10
Invesco
Georgia
$97.5M +$16.4M +208,499 +18%
HCM
11
Hoplite Capital Management
New York
$89.3M +$99.4M +1,262,359 New
State Street
12
State Street
Massachusetts
$77.8M +$595K +7,552 +0.7%
BIT
13
BlackRock Institutional Trust
California
$62.1M -$14.7M -186,681 -18%
Ameriprise
14
Ameriprise
Minnesota
$61.7M -$4.64M -58,938 -6%
Goldman Sachs
15
Goldman Sachs
New York
$59M +$58.9M +747,299 +866%
ClearBridge Investments
16
ClearBridge Investments
New York
$54.6M +$4.08M +51,801 +7%
American Century Companies
17
American Century Companies
Missouri
$48.7M +$20.5M +260,848 +61%
DCM
18
Daruma Capital Management
New York
$47.2M +$621K +7,879 +1%
VAM
19
Visium Asset Management
New York
$43.5M +$48.4M +614,800 New
Millennium Management
20
Millennium Management
New York
$38.6M +$36.7M +465,661 +583%
SFM
21
Soros Fund Management
New York
$37.6M +$41.9M +531,800 New
MCMC
22
Matrix Capital Management Company
New Hampshire
$36.8M +$1.55M +19,703 +4%
Northern Trust
23
Northern Trust
Illinois
$36M +$3.19M +40,506 +9%
Wells Fargo
24
Wells Fargo
California
$35.5M -$13M -165,448 -25%
ORI
25
Oak Ridge Investments
Illinois
$31.5M +$35.1M +445,861 New

PCRX Hedge Fund Activity: Q2 2015 in Review

187 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2015, worth a combined $3.03B — down 15% from $3.58B a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of PCRX and 31 opened new positions — a net loss of 16 holders — while 63 trimmed existing stakes and 73 added.

The largest buyer was Janus Henderson Investors US, adding an estimated $124M. The largest seller was Jennison Associates, cutting an estimated $92.5M.

  • 187 institutional investors held Pacira BioSciences (PCRX) as of Q2 2015, down from 205 in Q1 2015.
  • Funds reported $3.03B of Pacira BioSciences stock for Q2 2015, down 15% quarter-over-quarter.
  • 31 funds opened new Pacira BioSciences positions in Q2 2015 and 47 closed out, a net change of -16 holders.
  • The largest Pacira BioSciences buyer in Q2 2015 was Janus Henderson Investors US, an estimated $124M added.
  • The largest Pacira BioSciences seller in Q2 2015 was Jennison Associates, an estimated $92.5M sold.

Based on aggregated 13F filings for Q2 2015.